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(57) ABSTRACT 
Disclosed is an in vivo equine disease model and a method 
of preparing the disease model for equine herpesvirus-1 
neurological disease comprising a horse having a low pre-
exposure level of herpesvirus-specific CTL precursors 
wherein the horse is experimentally infected with a neuro-
pathogenic strain of equine herpesvirus or a mutant thereof. 
Also disclosed is a method of quantifying the risk factors 
and predicting the development of clinical neurologic signs 
of equine herpesvirus-1 neurological disease in a horse. Also 
described in the invention is the determination of the risk of 
developing the clinical neurologic signs by a mathematical 
equation. A new live, attenuated vaccine formulation is 
disclosed that is effective against neurologic disease due to 
equine herpesvirus-1. 
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EQUINE DISEASE MODEL FOR 
HERPESVIRUS NEUROLOGIC DISEASE 
AND USES THEREOF 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application connnences the national stage under 35 
U.S.C. §371 of PCT International Application No. PCT/ 
US2009/004409, filed on Jul. 29, 2009, which claims the 
priority benefit of U.S. Provisional Application No. 61/137, 
412, filed on Jul. 30, 2008. The prior applications are 
incorporated herein by reference in their entirety. 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH OR DEVELOPMENT 
Not Applicable 
NAMES OF PARTIES TO A JOINT RESEARCH 
AGREEMENT 
Not Applicable 
REFERENCE TO A "SEQUENCE LISTING" 
The material on a single compact disc containing a 
Sequence Listing file provided in this application is incor-
porated by reference thereto. 
BACKGROUND OF THE INVENTION 
Field of the Invention 
The present invention concerns quantifiable risk factors 
for the post-exposure development of equine herpesvirus-1 
neurological disease and their use to provide a new equine 
experimental disease model for evaluating and developing 
effective vaccines for the protection of horses against equine 
herpesvirus-1 neurological disease. The invention further 
relates to a new live, attenuated vaccine and its use to 
prevent neurological disease caused by equine herpesvirus-
1. 
Description of Related Art 
All patents and publications cited in this specification are 
hereby incorporated by reference in their entirety. 
2 
tics," Equine Vet J33:191-196 (2001); M. J. Studdert et al., 
"Outbreak of equine herpesvirus type 1 myeloencephalitis: 
new insights from virus identification by PCR and the 
application of an EHV-1-specific antibody detection 
5 ELISA," Vet Rec 153:417-423 (2003); S. M. ReedandR. E. 
Toribio, "Equine herpesvirus 1 and 4," Vet Clin North Am 
Equine Pract 20:631-642 (2004); T. A. Jackson and J. W. 
Kendrick, "Paralysis of horses associated with equine her-
pesvirus 1 infection," J Amer Vet Med Assoc 158:1351-1357 
10 (1971 ); K. M. Charlton et al., "Meningoencephalomyelitis in 
horses associated with equine herpesvirus 1 infection," Vet 
Pathol 13:59-68 (1976); P. B. Little and J. Thorsen, "Dis-
seminated necrotizing myeloencephalitis: a herpes-associ-
15 ated neurological disease of horses," Vet Pathol l3:l6l-l 7l 
(1976); H. Platt et al., "Pathological observations on an 
outbreak of paralysis in broodmares," Equine Vet J 12:118-
126 (1980); R. S. Greenwood and A. B. Simpson, "Clinical 
report of a paralytic syndrome affecting stallions, mares and 
20 foals on a Thoroughbred studfarm," Equine Vet J 12:113-117 
(1980); K. E. Whitwell and A. S. Blunden, "Pathological 
findings in horses dying during an outbreak of the paralytic 
form of Equid herpesvirus type 1 (EHV-1) infection," 
Equine Vet J24:13-19 (1992); C. W. Kohn and W.R. Fenner, 
25 "Equine herpes myeloencephalopathy," Vet Clin N Am: 
Equine Pract 3:405-419 (1987)). 
Although the specific innnune mechanisms required for 
control of EHV-1 neurologic disease are largely not estab-
lished, a well known innnunoeffector mechanism for con-
30 trolling the level of cell-associated viremia of other herpes-
viruses is cytotoxic T lymphocytes (CTL) (A. M. Arvin, 
"Cell-mediated innnunity to varicella-zoster virus," J Infect 
Dis 166:35-41 (1992); S. Martin et al., "Herpes simplex 
virus type 1 specific cytotoxic T lymphocytes recognize 
35 virus nonstructural proteins,"J Viral 62:2265-2273 (1988)). 
Later investigations of Kydd et al. demonstrated that resis-
tance to EHV-1 abortion in ponies was associated with high 
frequencies of pre-exposure, EHV-1 specific CTLp in the 
blood circulation (J. H. Kydd et al., "Pre-infection frequen-
40 cies of equine herpesvirus-1 specific, cytotoxic T lympho-
cytes Fcorrelate with protection against abortion following 
experimental infection of pregnant mares," Vet Immunol & 
Immunopathol 96:207-217 (2003)). However, the Kydd et 
al. study dealt solely with abortion as a disease outcome of 
45 EHV-1 infection and did not address the neurological mani-
festation of EHV-1 infection. Epizootics of neurological disease caused by equine her-
pesvirus-1 (EHV-1) have been reported with increasing 
frequency in the United States during the past several years 
(United States Department of Agriculture, "Equine herpes 
virus myeloencephalopathy: A potentially emerging dis- 50 
ease," USDA: APHIS: Veterinary Services: Centers for 
Epidemiology and Animal Health, Center for Emerging 
Issues Information Sheet, 2007). Characterized by high 
neurologic morbidity and case fatality rates, resistance to 
prevention by vaccination, and the ability to affect horses of 55 
all breeds and ages, EHV-1 myeloencephalopathy has the 
potential for causing catastrophic losses to both the welfare 
Recent molecular characterization of EHV-1 isolates 
recovered from outbreaks of neurologic disease has revealed 
that the majority of isolates are variant strains of the virus 
that possess an adenine (A) to guanine (G) base substitution 
at position 2254 of the gene that encodes the viral DNA 
polymerase (open reading frame #30; ORF30) (J. Nugent et 
al., "Analysis of equine herpesvirus type 1 strain variation 
reveals a point mutation of the DNA polymerase strongly 
associated with neuropathogenic versus non-neuropatho-
genic disease outbreaks," J Viral 80:4047-4060 (2006)). It 
has been postulated that this unique mutation in the catalytic 
subunit of the viral replication complex endows such virus 
strains with an enhanced replicative vigor that increases the 
number and severity of lesions of necrotizing vasculitis in 
the blood vessels of the central nervous system of the 
infected horse (K. E. Whitwell and A. S. Blunden, "Patho-
logical findings in horses dying during an outbreak of the 
paralytic form of Equid herpesvirus type 1 (EHV-1) infec-
tion," Equine Vet J 24:13-19 (1992); G. P. Allen and C. C. 
Breadthnach, "Quantification by real-time PCR of the mag-
nitude and duration of leukocyte-associated viraemia in 
of horses and the economy of equine-based businesses (M. 
T. Donaldson and C. R. Sweeney, "Equine herpes myelo-
encephalopathy," Compend Cantin Edu Pract Vet 19:864- 60 
871 (1997); W. D. Wilson, "Equine herpesvirus 1 myeloen-
cephalopathy," Vet Clin North Am Equine Pract 13:53-72 
(1997); R. W. Henninger et al., "Epidemic neurologic dis-
ease due to equine herpesvirus-1 at a university equestrian 
center," J Vet Intern Med 21:157-165 (2007); C. van Maanen 65 
et al., "Neurological disease associated with EHV-1 infec-
tion in a riding school: clinical and virological characteris-
US 9,642,908 B2 
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horses infected with neuropathogenic versus non-neuro-
pathogenic strains of equine herpesvirus-1," Equine Vet J 
38:252-257 (2006)). 
Concern has been voiced that genetic change in the herpes 
viral agent with a concomitant increase in its virulence is 
resulting in the neurological manifestation of EHV-1 infec-
tion that is increasing in incidence, morbidity and case 
fatality rates (United States Department of Agriculture, 
"Equine herpes virus myeloencephalopathy: A potentially 
emerging disease," USDA: APHIS: Veterinary Services: 
Centers for Epidemiology and Animal Health, Center for 
Emerging Issues Information Sheet, 2007). The increase in 
incidence of the high-mortality herpesviral neurological 
disease of horses that is not protected against by currently 
marketed vaccines has fueled genuine concerns about its 
effect on the future economic prosperity of the U.S. horse 
industry. Of particular alarm to the equine industry is its 
recent targeting of horses in riding/boarding stables and of 
young horses assembled at race track venues for training and 
racing, with consequent high mortality rates and severe 
economic losses to the boarding and racing sectors of the 
industry. Although efforts to develop a more effective, 
second-generation vaccine against the neurologic herpesvi-
rus disease are underway by several vaccine manufacturers, 
no equine disease model exists for assessing the effective-
ness of such experimental vaccines. 
In fact, a practical neurological disease model has never 
been created, either in connection with standard laboratory 
mice, rats or guinea pigs where the neurological effects of 
EHV-1 infection can never develop, or even from prior 
equine studies of EHV-1 in horses or ponies. Earlier chal-
lenge studies, including those reported in the published 
paper by T. O'Neill et al., "Determination of equid herpes-
virus I-specific, CDS+, cytotoxic T lymphocyte precursor 
frequencies in ponies," Vet Immunol & Immunopathol 
70:43-54 (1999), did not address the neurological manifes-
tation of EHV-1 infection or disease. Since the oldest group 
of 9-year-old ponies in that 1999 study showed frequencies 
4 
Vaccine 17(3): 237-244 (February 1999); P. A. M. van 
Woensel et al., "A mouse model for testing the pathogenicity 
of equine herpes virus-I strains," Journal of Virological 
Methods 54(1):39-49 (July 1995); M. K. Baxi et al., 
5 "Molecular studies of the acute infection, latency and reac-
tivation of equine herpesvirus-1 (EHV-1) in the mouse 
model," Virus Research 40(1):33-45 (January 1996). 
While the murine model has served its purpose as a model 
for simple EHV-1 infections characterized by clinical signs 
10 such as pyrexia (abnormally elevated body temperature) or 
loss of body weight, the mouse as an experimental model for 
studying the neurological disease and efficacious vaccine 
candidates in large horses has several drawbacks. First of all, 
the EHV-1 infection in the mouse never can progress to 
15 express the same breadth of neurological signs that plague 
the natural host, namely, horses, thus failing to provide a 
complete picture as a viral vaccine candidate model to 
permit adequate vaccination strategies in horses. For 
instance, myeloencephalopathic disease like that exhibited 
20 by herpesvirus infected horses does not develop in the 
experimental mouse model of herpesvirus disease. Sec-
ondly, a major adverse effect of infection in pregnant mares 
is the induction of spontaneous infectious abortions, which 
cannot be duplicated or investigated in the vaccination 
25 studies run in the classic murine model. Thirdly, without a 
solid understanding of the clinical signs and progression of 
the EHV-1 disease in horses, the vaccine candidates will not 
have broad applicability and activity to prevent more serious 
neurologic signs than simple infections caused by the single 
30 etiological agent in the mouse. More research on the pro-
gression of the disease in the natural host is necessary 
beyond the bare minimal effects from infection in the mouse. 
Fourthly, the detection of new mutant equine herpesviruses 
has further limited the application of the murine model as a 
35 practical animal model for vaccine purposes. 
Eventually, final testing of the safety and efficacy of the 
virus strains will take place in vivo in horses. Equine 
vaccines, which are commercially available and described in 
the art, are subsequently tested on horses, but typically only 
40 after the initial efficacy and safety studies in the classic 
murine model that leave a wide gap in vaccination data. For 
a case directly on point, the horse vaccines comprising a 
mutant EHV-1 or EHV-4 virus disclosed in U.S. Pat. No. 
of EHV-1 specific CTLp that were high before experimental 
infection, it was concluded by the co-authors that high CTLp 
frequency may correlate with immunity to EHV-1. Further-
more, the ponies never reached the point where they pre-
sented any neurological signs. Their blood analysis and 
physical characteristics are oflimited value, consequently, in 
determining the factors giving rise to neurological disease, 45 
the traits of a neurological disease model or the criteria 
useful in predicting development of neurological disease. 
7,060,282 are shown as being conventionally tested first 
through in vivo studies in laboratory mice. The patentees 
note the limitations of using the standard murine model to 
confirm protective activity in horses. They indicate that 
while pathogenicity of individual EHV-1 strains can be 
correlated from the mouse model to the behavior in the 
Previously, vaccination strategies have focused on the 
well-known murine model of EHV-1 infection in which the 
efficacy and safety of the EHV-1 vaccines are initially tested 50 natural equine host, more conclusive proof is obtained only 
from vaccination trials in horses. Patentees further complain 
that the level of protection against challenge infection and 
ultimately in preventing abortion in pregnant mares can only 
be established in the target animal and, thus, the initial 
in vivo in mice rather than directly in horses ( see, for 
example, A. R. Frampton et al., "Meningoencephalitis in 
mice infected with an equine herpesvirus 1 strain KyA 
recombinant expressing glycoprotein I and glycoprotein E," 
Virus genes 29(1):9-17 (August 2004); C. F. Colle et al., 
"Equine herpesvirus-1 strain KyA, a candidate vaccine 
strain, reduces viral titers in mice challenged with a patho-
genic strain, RacL," Virus Research 43(2):111-124 (August 
1996); T. Kondo et al., "A protective effect of epidermal 
powder immunization in a mouse model of equine herpes- 60 
virus-I infection," Virology 318(1):414-419 (January 2004); 
C. Walker et al., "Comparison of the pathogenesis of acute 
equine herpesvirus 1 (EHV-1) infection in the horse and the 
mouse model: a review," Veterinary Microbiology 68(1):3-
13 (August 1999); K. M. Ruitenberg et al., "DNA-mediated 
immunization with glycoprotein D of equine herpesvirus 1 
(EHV-1) in a murine model of EHV-1 respiratory infection" 
55 murine testing is of limited value in the final analysis. 
There is a definite art-recognized problem with the classic 
mouse model that the present invention solves by develop-
ing the first equine disease model for the successful repro-
duction of herpesvirus-1 neurological disease in the horse. 
It is therefore an important object of the present invention 
to provide a unique equine experimental disease model that 
is useful for evaluating and developing safe and effective 
vaccines in the protection of horses against equine herpes-
virus infections and, more specifically, against equine her-
65 pesvirus-1 neurological disease. 
It is a further important object of the present invention to 
identify the parameters in equine herpesvirus inoculated 
US 9,642,908 B2 
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FIG. 1 illustrates the relationships among peak magnitude 
ofviremia, pre-infection CTLp frequency and development 
of clinical neurologic disease in 24 horses following expo-
sure to neuropathogenic EHV-1. White circles represent 
horses that are highly correlated with post-inoculation devel-
opment of clinical disease and particularly to find the 
quantifiable risk factors that are directly associated with the 
development of clinical neurological signs in horses exposed 
to equine herpesvirus-1. 5 horses with neurologic signs while the black circles stand for 
the horses without neurologic signs. EHV-1 DNA present in 
equine peripheral blood mononuclear cells (PBMC) was 
quantified by real-time qPCR and the amount expressed as 
It is another important object of the invention to find an 
effective modified live, virus vaccine that protects horses 
against neurological disease due to infection caused by 
equine herpesvirus-1. While presently known EHV-1 vac-
cines that claim protection against neurologic disease as well 
10 
as respiratory disease and abortion are largely based on 
inactivated viruses (see, for example, U.S. Pat. Nos. 7,323, 
178 and 7,226,604), it is art-recognized that live and attenu-
ated viral vaccines, as a general rule, can induce a better 
immune response. Therefore, this goal of the present inven-
tion is to provide a new and improved live, attenuated 15 
vaccine formulation that stimulates a protective immune 
response against neurologic disease due to equine herpes-
virus-1. 
Further purposes and objects of the present invention will 
appear as the specification proceeds. 
The foregoing objects are accomplished by providing a 
novel equine disease model, the determination of the quan-
tifiable risk factors for the post-exposure development of 
equine herpesvirus-1 neurological disease and a unique 
equine herpesvirus-1 vaccine as described herein. 
BRIEF SUMMARY OF THE INVENTION 
The present invention relates to a new disease model for 
equine herpesvirus-1 neurological disease comprising a 
horse possessing the following quantifiable risk factors that 
highly correlate with the post-exposure development of 
equine herpesvirus-1 neurological disease: (1) the magni-
tude of post-infection, systemically circulating EHV-1 
infected leukocytes (viremic load); (2) the pre-exposure 
frequency of circulating cytotoxic T lymphocyte precursors 
(CTLp) specific for EHV-1; (3) the ORF30-2254 genotype 
log10 of the fold-difference relative to that present in a 
reference calibrator PBMC DNA (relative quantification; 
RQ). Determination in equine PBMC of the frequency of 
CTL precursors (CTLp) specific for EHV-1 was done by 
limiting dilution analysis. 
FIG. 2 shows the mean±SE daily values for magnitude of 
leukocyte-associated (PBMC-associated) viremia in 12 
young (<15 years, shown by darkly shaded area) and 12 old 
(>20 years, shown by lightly shaded area) horses following 
intranasal inoculation with a neuropathogenic strain of 
EHV-1. EHV-1 DNA present in equine peripheral blood 
20 mononuclear cells (PBMC) was quantified by real-time 
qPCR and the amount expressed as the fold-difference 
relative to that present in a reference calibrator PBMC DNA 
(relative quantification; RQ). The results are presented as an 
"area-fill plot" to visually illustrate the two-dimensional 
25 character (magnitude and duration) of EHV-1 viremia, in 
which the total viral load experienced by the infected horse 
is proportional to the shaded area beneath each curve. 
Standard errors of the mean RQ values for each age group 
of 12 horses on each sampling day post-inoculation are 
30 indicated by the error bars. The differences between the two 
age groups of mares in their mean magnitude of EHV-1 
viremia are significant at P=s0.05 for post-inoculation days 
4 through 10. 
FIG. 3 shows a comparison of the mean±SE daily mag-
35 nitude of leukocyte-associated (PBMC-associated) viremia 
in 24 elderly horses (>20 years) following inoculation with 
either an ORF30 A2254 strain (T262, the wild-type EHV-1 
strain shown by darkly shaded area; n=12 horses) or an 
ORF30 G2254 strain (T953, the mutant EHV-1 strain shown 
of the infecting strain of EHV-1; and ( 4) age category of the 
exposed horse. Also embraced by the present invention is the 
previously unknown identification of these risk factors that 
directly correlate to the development of clinical signs of 
neurological disease in horses exposed to equine herpesvi-
rus-1 and making novel use of such identification in a new 
method of quantifying the risk factors and predicting the 
development of clinical neurologic signs of equine herpes-
virus-1 neurological disease. Of the identified risk factors, 
infection by an ORF30 G2254 strain of EHV-1 has the 
strongest association with the probability of clinical pro-
gression of the herpesviral infection to clinically overt 
neurological disease. Important embodiments of the inven-
tion are thus drawn to the in vivo equine disease models 
wherein the horse is experimentally infected, typically 
through intranasal administration, with a neuropathogenic 
strain of equine herpesvirus or a mutant thereof, such as the 
ORF30 G2254 strain ofEHV-1, in which the horse has a low 
pre-exposure level of herpesvirus-specific CTL precursors 
and/or is about 20 years of age or older as well as the method 55 
of preparing the in vivo equine disease model for EHV-1 
neurological disease. An additional embodiment of the 
invention employs a live, attenuated strain of equine her-
pesvirus or a mutant thereof as the antigen in a modified 
vaccine and its use to protect horses against neurological 
disease due to infection caused by equine herpesvirus-1. 
40 by lightly shaded area; n=12 horses) ofEHV-1. EHV-1 DNA 
present in equine peripheral blood mononuclear cells 
(PBMC) was quantified by real-time qPCR, and the amount 
was expressed as log10 of the fold-difference relative to that 
present in a reference calibrator PBMC DNA (relative 
45 quantification; RQ). The results are presented as an "area-fill 
plot" to visually illustrate the two-dimensional character 
(magnitude and duration) of EHV-1 viremia, in which the 
total viral load inflicted upon the infected horse is propor-
tional to the shaded area beneath each curve. Standard errors 
50 of the mean log10 RQ values for each treatment group of 12 
horses are indicated by the error bars. The differences in the 
mean magnitude of EHV-1 viremia resulting from inocula-
tion with the two genetic strains of EHV-1 are significant at 
P=s0.05 for post-inoculation days 4 through 12. 
FIG. 4 illustrates the analysis of data for relationship 
between pre-infection serum neutralizing antibody (SNA) 
titer against EHV-1 and either peak magnitude of EHV-1 
viremia or development of clinical neurologic disease in 24 
horses following exposure to neuropathogenic EHV-1. 
60 White circles represent horses with neurologic signs while 
the black circles stand for the horses without neurologic 
signs. EHV-1 DNA present in equine peripheral blood 
mononuclear cells (PBMC) was quantified by real-time BRIEF DESCRIPTION OF THE DRAWINGS 
The background of the invention and its departure from 65 
the art will be further described herein below with reference 
to the accompanying drawings, wherein: 
qPCR and the amount expressed as log10 of the fold-
difference relative to that present in a reference calibrator 
PBMC DNA (relative quantification; RQ). Determination of 
serum levels of neutralizing antibodies specific for EHV-1 
US 9,642,908 B2 
7 
was done by a microneutralization assay. The correlation 
coefficient, r, between the two plotted variables is -0.31. The 
statistical probability (P value) that no linear relationship 
exists between pre-exposure SNA titer and magnitude of 
post-exposure EHV-1 viremia is 0.144. 
DETAILED DESCRIPTION OF THE 
INVENTION 
In accord with the present invention, there is provided a 
unique equine experimental disease model of equine her-
pesvirus-1 (hereinafter referred to as "EHV-1 ") infection 
and neurological disease, that is highly useful for the evalu-
ation and the development of safe and efficacious vaccines 
for the protection of horses against debilitating neurological 
disease. The innovative neurological disease model of 
EHV-1 is defined and the disease is reproduced in horses for 
the first time. Understanding the pathogenesis in horses and 
quantifying the risk factors for the post-exposure incidence 
of EHV-1 disease permit the valuable development of vac-
cine strategies that can target the specific signs of disease. As 
a result of this invention, it is now possible to considerably 
improve and to preferentially target the mode of action of 
EHV-1 vaccine candidates to obtain a more reproducible and 
reliable outcome than previously achievable. 
An important embodiment of this invention encompasses 
the particular in vivo equine disease model in which an 
experimental horse having a low pre-exposure level of 
herpesvirus-specific CTL precursors and/or is about 20 years 
of age or older is challenged with a neuropathogenic strain 
of equine herpesvirus or a mutant thereof. Distinguishing 
from natural infections, the horse of the present invention is 
inoculated (i.e., artificially infected) by a person who gives 
8 
neurological disease of horses. The innovativeness of the 
invention is found in the discovery of the quantifiable risk 
factors that permit the selection of the experimental horse 
subjects and the challenge strain of herpesvirus that allow 
5 reproduction of the neurological disease in a high proportion 
of virus-inoculated horses. In view of this discovery, the 
present invention further embraces a new method of quan-
tifying risk factors and predicting the development of clini-
cal neurologic signs of equine herpesvirus-1 neurological 
10 disease in a horse. The unique method comprises the two 
steps of: (a) determining the pre-infection CTLp frequency 
to be less than approximately 40 EHV-1 specific CTLp per 
106 (i.e., per million) PBMC( equine peripheral blood mono-
nuclear cells) and/ or determining the age of the horse to be 
15 approximately 20 years of age or older; and (b) determining 
the post-infection viremic load following exposure to 
EHV-1 to be approximately 10-fold or more over the viremic 
load present in horses following exposure to a non-neuro-
pathogenic strain of EHV-1. Desirably, step (a) embraces 
20 determining the pre-infection CTLp frequency to be less 
than approximately 20 EHV-1 specific CTLp per 106 PBMC 
and, more desirably, determining the pre-infection CTLp 
frequency to be less than approximately 10 EHV-1 specific 
CTLp per 106 PBMC while step (b) independently encom-
25 passes determining the post-infection viremic load follow-
ing exposure to EHV-1 to be approximately 100-fold or 
more greater than the viremic load present in horses follow-
ing exposure to a non-neuropathogenic strain ofEHV-1 and, 
even more desirably, determining the post-infection viremic 
30 load following exposure to EHV-1 to be greater than 1000-
fold higher than the viremic load present in horses following 
exposure to a non-neuropathogenic strain of EHV-1. 
Up until the present invention, the risk factors associated 
with EHV-1-induced myeloencephalopathy in horses had 
35 not yet been fully investigated. In addition, certain research-
ers provided incorrect conclusions regarding the factors 
giving rise to EHV-1 disease, which clouded the animal 
health issues. This invention represents a real advancement 
in the veterinary arts since the parameters in EHV-1 inocu-
an effective challenge dose to the horse, typically by intra-
nasal administration of EHV-1 although other standard 
routes of administering the viral agent such as intrarectal, 
oral, intramuscular, intradermal, subcutaneous and the like 
are possible. The amount of an effective challenge dose, 
which is the quantity of EHV-1 sufficient to cause signs of 
infection, can be readily determined and titrated through 
routine testing in horses. The neuropathogenic strain of 
EHV-1 or the mutant thereof includes, but is not limited to, 
the ORF30 G2254 strain ofEHV-1 such as T953, Army 183, 
Ab4, etc. and others known to those of ordinary skill in the 
veterinary viral art. Preferably, the experimental disease 45 
model has been created by intranasal inoculation with an 
effective challenge dose of the neuropathogenic ORF30 
40 lated horses that are highly correlated with post-inoculation 
presentation of clinical neurological disease are now fully 
identified. 
Although the underlying basis for predicting which horses 
will make effective experimental subjects is seen to be the 
magnitude of CTLp circulating in the blood, it is also now 
unexpectedly found that the aged horses coincidentally but 
almost uniformly exhibit low levels of CTLp as a result of 
the waning immune system that accompanies aging. Con-
sequently, the invention also includes the bare determination 
of the horse age, in particular, about 20 years old or more, 
as a valid and sole criterion for predicting and selecting 
G 2254 strain of EHV-1 and the horse possesses high levels of 
post-infection, leukocyte-associated viremia. Of particular 
benefit as a highly desirable experimental model of this 50 
invention is the in vivo equine disease model for EHV-1 
neurological disease that develops or presents with clinical 
signs of myeloencephalopathy. 
Another important embodiment of the present invention 
relates to the method of preparing the in vivo equine disease 55 
model for EHV-1 neurological disease which comprises 
obtaining a horse that possesses low pre-infection levels of 
EHV-1 specific CTL precursors and/or is roughly 20 years of 
age or older and inoculating the horse intranasally with an 
effective challenge dose of a neuropathogenic strain of 60 
EHV-1, preferably the ORF30 G2254 strain of EHV-1 such 
as, for example, the T953, Army 183, Ab4 strains ofEHV-1, 
etc. 
experimental subjects for the disease model. 
Insofar as the age of the horse disease model is concerned, 
the present invention further embraces the use of foals, 
typically as young as roughly one week old to just about one 
year old in age, in which low pre-infection levels ofEHV-1 
specific CTL precursors are created and induced by suitable 
immune-suppressing agents. While a horse of any age can be 
immune-suppressed, the foal, which does not yet exhibit low 
levels of CTLp naturally, can be immunosuppressed desir-
ably with conventional immunosuppressing drugs to impair 
the CTL function. The immune-suppressing agents useful in 
the present invention include, but are not limited to, anti-
metabolites such as azathioprine, mycophenolate mofetil, Commercial vaccine developers can use the reproducible, 
neurologic disease model for equine herpesvirus myeloen-
cephalopathy for assessment of the protective efficacy of 
their candidate antiviral vaccines against the herpesviral 
65 etc.; corticosteroids, calcineurin inhibitors such as 
cyclosporine, tacrolimus, etc.; sirolimus; polyclonal anti-
body therapy; monoclonal antibody therapy using, for 
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example, OKT3 or daclizumab and basiliximab; and the 
like. Preferably, the immunosuppression is produced by 
dexamethasone or another comparable corticosteroid. 
10 
sured by micro-neutralization test), and EHV-1-specific 
cytotoxic T lymphocyte precursors (CTLp; measured by 
limiting dilution analysis of chromium-51 release assay 
results). The data are examined for statistically significant Inducing immunosuppression can be achieved by any 
standard technique known in the art (see, e.g., N. R. Barshes 
et al., "Pharmacologic Immunosuppression," Frontiers in 
Bioscience 9:411-420 (Jan. 1, 2004); T. J. Cutler et al., 
"Immunosuppression against Sarcocystis neurona in normal 
and dexamethasone-treated horses challenged with S. neu-
rona sporocysts," Veterinary Parasitology 95:197-210 
(2001); D. B. Tumas et al., "Corticosteroid immunosuppres-
sion and monoclonal antibody-mediated CD5+T lympho-
cyte depletion in normal and equine infectious anaemia 
virus-carrier horses," J Gen Virology 75:959-968 (1994)) By 
way of an example relevant to the present invention, a foal 
less than one year old in age is injected intravenously with 
1 mg/kg of dexamethasone per body weight per day for 
approximately nine days to induce immunosuppression 
where the CTL function becomes impaired. About four to 
five days after treatment with dexamethasone is completed, 
the young horse possessing the impaired CTL function is 
then challenged with a suitable infecting amount of a 
neuropathogenic strain of EHV-1 strain to create the disease 
model of this invention. 
5 associations between values of the measured parameters and 
the occurrence of post-challenge clinical neurologic disease 
in the experimentally infected horses. Correlations between 
age-category or breed of the EHV-1 inoculated horses and 
post-exposure development of neurologic disease are also 
10 examined. 
The results of the challenge studies show that nine of the 
thirty-six EHV-1 inoculated horses develop clinical signs of 
central nervous system disease (ataxia, hindlimb paresis or 
paralysis, bladder atony, and/or recumbency). Post-exposure 
15 development of clinically apparent neurologic deficits in the 
study horses is positively correlated with infection by a 
neuropathogenic strain ofEHV-1, advanced age (>20 years), 
elevated post-exposure viremic load, and a low pre-exposure 
level of virus-specific CTLp. Unexpectedly, the pre-infec-
20 tion serum neutralizing antibody titer has the least correla-
tion to development of disease after exposure to EHV-1. In 
addition, no significant correlation is observed between 
horse breed and the post-infection development of neuro-
logic signs. 
Also surprising is the finding that the category of horse at 
greatest risk for development of myeloencephalopathy fol-
lowing infection by EHV-1 is the elderly horse (>20 years) 
exposed to a neuropathogenic strain of the virus (ORF30 
G2254) and possessing low pre-infection levels of EHV-1 
30 specific CTL precursors and high levels of post-infection, 
leukocyte-associated viremia. By contrast, horses possess-
ing high levels of pre-existing, EHV-1 specific CTL precur-
sors, regardless of age, strain of virus, or SNA titer, are more 
likely to control the magnitude of post-infection, leukocyte-
Demonstration of characteristics whose quantitative lev- 25 
els are so highly correlated with development of post-
infection EHV-1 neurological disease in the horse would be 
useful to the veterinary industry in the identification of 
practical targets for the action of future EHV-1 vaccines and 
antiviral drugs. As such, the primary goal met by the present 
invention is the recognition of parameters that are statisti-
cally associated with development of post-exposure, EHV-1 
neurological disease; i.e., to identify disease risk factors in 
EHV-1 inoculated horses that are highly correlated with 
post-inoculation development of clinical neurologic disease. 
Identification of such neurologic risk-associated parameters 
gives definitive and quantifiable prognostic indicators for 
development of clinical EHV-1 myeloencephalopathy fol-
lowing infection by the herpesvirus. 
35 associated viremia and the subsequent development of 
EHV-1 neurologic disease. These observations serve to 
identify CTLp as one of the critical immune requirements 
for protective immunity to EHV-1 induced myeloencepha-
lopathy. The importance of achieving high levels of vaccine 
A secondary goal satisfied by the current invention is the 
clarification of the immunological mechanisms that horses 
use for controlling the magnitude of EHV-1 cell-associated 
viremia and its vasculitis-mediated sequelae of ischemic 
damage to the equine central nervous system (CNS). The 
latter information provides valuable insight into the types of 
immunologic effector responses required to be elicited by 
vaccines for successful immunoprevention of EHV-1 para-
lytic disease and serves as reliable, in vitro immune corre-
lates of vaccine protection against the neurologic disease. 
40 induced CTL immunity in groups of horses at high risk for 
exposure to neuropathogenic strains of EHV-1 is clearly 
indicated from the results of these studies. 
The results establish a strong association (P=<0.01 by 
Fisher's exact test) between the ORF30 genotype (A2254 or 
45 G 2254) of the infecting strain of EHV-1 and the subsequent 
risk for development of clinically apparent neurologic defi-
cits in the infected horse. While none of 12 mares inoculated 
with an ORF30 A2254 EHV-1 strain exhibit neurologic signs, 
As a further aspect of the present invention, it has been 50 
observed that the risk of developing the clinical neurologic 
signs is determined according to an equation y=a+bx 
wherein y is the peak viremic load, a=2.97, b=-0.027 and 
the variable x is the pre-infection CTLp frequency. By this 
equation, a linear relationship or a correlation coefficient 55 
statistic r between the two numerical variables ofy and xis 
-0.79 is indicative of the risk of developing the clinical 
neurologic signs. 
Illustrated in depth in the below examples, thirty-six 
adult, mixed breed, horse mares are inoculated intranasally 60 
with live, virulent strains of EHV-1. Blood samples, which 
are collected daily from the thirty-six experimental horses 
before and after challenge inoculation with either non-
neuropathogenic (ORF30 A2254) or neuropathogenic 
(ORF30 G2254) strains of EHV-1, are analyzed for quanti- 65 
tative levels of leukocyte-associated viremia (measured by 
real-time qPCR), serum neutralizing antibody (SNA; mea-
8 of 12 age- and gender-matched horses inoculated with an 
ORF30 G2254 strain of EHV-1 develop severe neurologic 
complications, with euthanasia required in 6 of the 8 neu-
rologically affected animals. Of the several potential risk 
factors evaluated in this study, infection by an ORF30 G2254 
strain of EHV-1 is found to be most strongly associated with 
the probability of clinical progression of the viral infection 
to clinically overt neurological disease. 
The data also establish a strong association (P=0.009 by 
Fisher's exact test) of the clinical progression of EHV-1 
infection to neurological disease with the age-category of 
the inoculated horse. The risk for development of EHV-1 
paralytic disease following exposure to a neuropathogenic 
genotype of the virus was 8-fold greater in elderly horses 
(>20 years) than in young to middle age adult horses (<15 
years). Comparison of the post-inoculation viremic load of 
EHV-1 infected leukocytes present in the 12 elderly and 12 
young experimental horses revealed that the mean, peak 
magnitude of cell-associated viremia was 100-fold greater in 
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the elderly horse group. Thus, the quantitative load of 
circulating virus that follows infection by EHV-1 was 
defined as a major risk factor (P=<0.001 by analysis of 
variance test) for post-exposure development of EHV-1 
CNS disease. The relatively greater susceptibility of elderly 5 
horses for development of EHV-1 neurological disease pro-
vides an experimental, neurologic disease model which may 
prove useful for assessment of vaccine efficacy against 
EHV-1 myeloencephalopathy. 
To investigate the role of memory CTL specific for 10 
neuropathogenic strains of EHV-1 as effectors for reducing 
the magnitude of post-infection viremia, quantitative esti-
mates of the pre-exposure frequency of EHV-1 specific CTL 
precursors (CTLp) in the experimental horses are deter-
mined herein below by limiting dilution analysis of Cr-51 15 
release assays. The results in connection with the present 
invention identify pre-exposure frequency ofEHV-1 specific 
CTLp as a strong correlate (regression correlation coeffi-
cient=-0.71) of the post-infection magnitude of cell-associ-
ated viremia and also as a statistically significant (P=<0.01 20 
by logistic regression analysis) correlate of protective immu-
nity against the myeloencephalopathy caused by infection of 
horses with neuropathogenic strains of EHV-1. These find-
ings suggest a role of CTL immune responses of the horse 
in maintaining immunological control of EHV-1 viremia. 25 
Such results support the view that a critical-mass reservoir 
12 
against viral infection but also protects against the debili-
tating and often fatal EHV-1 myeloencephalopathy. A dis-
turbing characteristic of the emerging hypervirulent, neuro-
pathogenic mutants of equine herpesvirus-1 is their inability 
to be curtailed by the level or type of immunity engendered 
by current-generation vaccines for EHV-1. The development 
of second-generation vaccines against the mutant herpesvi-
rus requires an equine neurologic disease vaccination-chal-
lenge model in which candidate vaccines can be tested for 
protective efficacy against EHV-1 myeloencephalopathy. 
The real benefit of the present invention can be readily seen 
in the development and validation of the unique EHV-1 
neurologic disease model in horses for practical use in 
vaccination-challenge studies for the evaluation of the neu-
rologic protective efficacy of candidate vaccines. 
Quantitative parameters ( e.g., viral genotype, age, and 
levels ofviremia and antiviral cellular immunity (CTLp )) in 
EHV-1 inoculated horses, that are highly correlated with 
post-inoculation development of neurologic disease and 
identified herein, serve to define the composition of the 
experimental disease model of the present invention. Con-
tributing to the high rate of experimentally produced EHV-1 
neurologic disease in virus-challenged horses are the use of 
(1) horses with low levels of antiviral cellular immunity as 
subjects for vaccination and challenge, and (2) a particularly 
neuropathogenic challenge strain ofEHV-1 (a Findlay 2003 
isolate that was originally obtained from an outbreak of 
EHV-1 disease among 135 horses stabled at the University 
of Findlay Equestrian Center, Findlay, Ohio and subse-
quently described in R. W. Henninger et al., "Epidemic 
neurologic disease due to equine herpesvirus-1 at a univer-
sity equestrian center," J Vet Intern Med 21: 157-165 (2007)). 
The presently developed EHV-1 neurologic disease model is 
evaluated by studies that determine a significant level of 
of circulating memory CTL, in place at the moment and 
location of virus exposure and capable of being activated 
into functional CTL with specific cytolytic activity against 
EHV-1, is required for controlling EHV-1 neurological dis- 30 
ease. In order to achieve protective efficacy against EHV-1 
myeloencephalopathy by vaccination, it follows that the 
vaccines must be able to drive the equine immune response 
toward the production of such cytolytically functional, 
effector CTL. 35 immune protection against EHV-1 neurologic disease is 
unexpectedly established in horses by vaccination with a 
live, non-neuropathogenic strain of EHV-1. 
On the other hand, it is now discovered that the level of 
antibodies present prior to virus inoculation surprisingly 
does not correlate with protection against challenge with 
neuropathogenic EHV-1. After performing measurements of 
EHV-1 specific SNA present in the experimental horses at 
the time of virus inoculation, the results failed to reveal any 
significant relationship between pre-exposure SNA titer and 
the magnitude of post-infection viremia. The intracellular 
location of EHV-1 during most of its infection cycle within 
the horse may limit the effectiveness of virus neutralizing 
antibody in controlling the level of cell-associated EHV-1 
vJremia. 
In sum, of the six neurologic risks evaluated for relation 
A further important embodiment of the present invention 
is drawn to novel live, attenuated viral vaccines containing 
40 a non-neuropathogenic strain of EHV-1 having the ORF30 
A2254 genotype, for example, the T262 strain or a neuro-
pathogenic strain ofEHV-1 having the ORF30 G2254 geno-
type such as the T953, Army 183 or Ab4 strain, as the viral 
antigen alone or in combination with one or more other 
45 antigens and a method of administering the vaccine to 
prevent or to minimize the effects of viral infection that can 
progress to neurologic disease as well as to protect against 
development of neurologic disease including myeloen-
cephalopathy caused by the neuropathogenic viruses. 
Advantageously, the new method protects horses in need 
of protection against neurologic disease due to neuropatho-
genic EHV-1 by administering to the horse an immunologi-
cally effective amount of the vaccine according to the 
invention. The immunologically effective amount or the 
to the presentation of the disease entity caused by EHV-1 
((1) the magnitude of post-infection, systemically circulat- 50 
ing EHV-1 infected leukocytes (viremic load); (2) the pre-
exposure frequency of circulating cytotoxic T lymphocyte 
precursors (CTLp) specific for EHV-1; (3) the pre-infection 
titer of serum neutralizing antibody to EHV-1; ( 4) the 
ORF30-2254 genotype of the infecting strain of EHV-1; (5) 
breed of horse; and ( 6) age category of the exposed horse), 
55 immunogenic amount that inoculates the horse can be easily 
determined or readily titrated by routine testing. An effective 
amount is one in which a sufficient immunological response 
to the vaccine is attained to protect the horse exposed to the 
EHV-1 virus which causes neurologic disease and myelo-
it is determined that the pre-infection titer of serum neutral-
izing antibody to EHV-1 and the breed of horse have no 
correlation of the progression of EHV-1 infection to neuro-
logical disease. Surprisingly, infection by an ORF30 G2254 
strain of EHV-1 is determined to be most strongly connected 
to the probability of progression of the viral infection to 
clinically overt neurological disease. 
A practical advantage of the present invention is found in 
the novel use of the experimental horse model to evaluate 
the efficacy of broad-spectrum candidate vaccines for the 
protection of horses against EHV-1 that not only protects 
60 encephalopathy. Preferably, the horse is protected to an 
extent in which one to all of the adverse physiological signs 
or effects of the neurologic viral disease are significantly 
reduced, ameliorated or totally prevented. 
The foal's immunization schedule often begins at the age 
65 of about three to about six months of age. The vaccine can 
be administered in a single dose or in repeated doses by 
administering a second booster injection approximately four 
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to six weeks after the primary immunization and then 
optionally giving a third booster injection another month 
later. Thereafter, the vaccine can be given every three 
months or annually depending on formulation and route of 
administration. Concentration of the virus in the vaccine 
may range, for example, from about 4 logs to about 9 logs 
TCID50/dose and a reasonable dosage may be given to the 
horse in the amount of about 6 to about 7 logs TCID50/dose, 
but should not contain an amount of virus-based antigen 
sufficient to result in an adverse reaction or physiological 
signs of viral infection. Methods are known in the art for 
determining or titrating suitable dosages of active antigenic 
agent based on the weight of the horse, concentration of the 
antigen and other typical factors. 
The vaccine of the invention can conveniently be admin-
istered orally, intranasally, intramuscularly, intrarectally, 
transdermally (i.e., applied on or at the skin surface for 
systemic absorption) or intradermally (i.e., injected or oth-
erwise placed under the skin). Desirably, the routes of 
administration are the oral, intranasal and intramuscular 
routes. However, the oral and intranasal routes of adminis-
tration are most preferred for inducement of strong local as 
well as systemic immune responses. 
When administered as a liquid, the present vaccine may 
be prepared in the form of an aqueous solution, syrup, an 
elixir, a tincture and the like. Such formulations are known 
in the art and are typically prepared by dissolution of the 
antigen and other typical additives in the appropriate carrier 
or solvent systems. Suitable carriers or solvents include, but 
are not limited to, water, saline, ethanol, ethylene glycol, 
glycerol, etc. Optional additives are, for example, certified 
dyes, flavors, sweeteners and antimicrobial preservatives 
such as antibiotics or thimerosal (sodium ethylmercurithio-
salicylate) where permitted by law. Such solutions may be 
stabilized, for example, by addition of partially hydrolyzed 
gelatin, sorbitol or cell culture medium, and may be buffered 
by conventional methods using reagents known in the art, 
such as sodium hydrogen phosphate, sodium dihydrogen 
phosphate, potassium hydrogen phosphate, potassium dihy-
drogen phosphate, a mixture thereof, and the like. 
Liquid formulations also may include suspensions and 
emulsions that contain suspending or emulsifying agents in 
combination with other standard co-formulants. These types 
14 
adjuvant may be administered at the same time and at the 
same site as the vaccine, or at a different time as a booster. 
Adjuvants also may advantageously be administered to the 
horse in a mariner or at a site different from the manner or 
5 site in which the vaccine is administered. Suitable adjuvants 
include, but are not limited to, metabolizable oils of plant or 
animal origin such as squalene (2,6,10,15,19,23-hexam-
ethyl-2,6,10,14,18,22-tetracosahexaene) or preferably, 
squalane (2,6, 10, 15,19,23-hexamethyl-tetracosane ), non-
10 ionic block polymers or block copolymers based on ethylene 
oxide and propylene oxide, for example, polyoxypropylene-
polyoxyethylene block copolymers (also known as (poly 
( ethylene oxide )-block-poly(propylene oxide )-block-poly 
(ethylene oxide) or Poloxamer block copolymers NF) such 
15 as Pluronic® (commercially available from BASF Corpo-
ration, Mount Olive, N.J.), saponin such as Qui! A (com-
mercial name of a purified form of Quillaja saponaria, 
available from Iscotec AB, Sweden and Superfos Biosector 
a/s, Vedbaek, Denmark), ethylene/maleic copolymers such 
20 as EMA-31 ® (a linear ethylene/maleic anhydride copolymer 
having approximately equal amounts of ethylene and maleic 
anhydride, having an estimated average molecular weight of 
about 75,000 to 100,000, commercially available from Mon-
santo Co., St. Louis, Mo.), acrylic acid copolymers, acrylic 
25 acid copolymer emulsions such as Neocryl® (an unco-
alesced aqueous acrylic acid copolymer of acrylic acid and 
methacrylic acid mixed with styrene, commercially avail-
able from Polyvinyl Chemicals, Inc., Wilmington, Mass.), 
mineral oil emulsions such as MVP® (an oil-in-water emul-
30 sion oflight mineral oil, commercially available from Mod-
em Veterinary Products, Omaha, Nebr.) or mixtures thereof 
and the like. Other suitable adjuvants include, for example, 
aluminum hydroxide (alum), immunostimulating complexes 
(ISCOMS), cytokines (like IL-1, IL-2, IL-7, IL-12, IFN-a, 
35 IFN-~, IFN-y, etc.), monophosphoryl lipid A (MLA), 
muramyl dipeptides (MDP), aluminum potassium sulfate, 
heat-labile or heat-stable enterotoxin isolated from Escheri-
chia coli, cholera toxin or the B subunit thereof, diphtheria 
toxin, tetanus toxin, pertussis toxin, Freund's incomplete or 
40 complete adjuvant, etc. Toxin-based adjuvants, such as 
diphtheria toxin, tetanus toxin and pertussis toxin may be 
inactivated prior to use, for example, by treatment with 
formaldehyde to make the corresponding toxoid. A particu-
of liquid formulations may be prepared by conventional 
methods. Suspensions, for example, may be prepared using 45 
a colloid mill. Emulsions, for example, may be prepared 
using a homogenizer. 
larly preferred adjuvant for use in the intramuscular formu-
lations of the invention is the unique adjuvant Metastim® (a 
registered trademark of Wyeth, Madison, N.J. comprising 
squalane and Pluronic® L-121). 
Parenteral formulations designed for intramuscular injec-
tion and the like require proper isotonicity and pH buffering 
to the level of equine body fluids and tissues. Isotonicity can 50 
be appropriately adjusted with sodium chloride and other 
salts as needed. Suitable solvents, such as ethanol or pro-
pylene glycol, can be used to increase the solubility of the 
ingredients in the formulation and the stability of the liquid 
preparation. Further additives that can be employed in the 55 
present vaccine include, but are not limited to, dextrose, 
conventional antioxidants and conventional chelating agents 
such as ethylenediamine tetraacetic acid (EDTA). Parenteral 
dosage forms must be sterilized prior to use. 
An adjuvant, which may be administered in conjunction 60 
with the vaccine of the present invention, is a substance that 
increases the immunological response of the horse to the 
vaccine. Since the strain of EHV-1 will be administered as 
The equine vaccine of the invention may remain univalent 
or be made multivalent and contain one or more additional 
antigens to promote broad spectrum immunological activity. 
The multivalent vaccine may include, but is not limited to, 
other equine viruses such as, for example, killed EHV-4, 
killed or live EHV-5, killed or live Equine Influenza Virus, 
killed Eastern, Western, and Venezuelan Encephalomyelitis 
viruses, inactivated West Nile Virus, or recombinant proteins 
or recombinant vectors expressing proteins from these 
viruses such as live canarypox vectors, live African Horse 
Sickness virus or recombinant vectors expressing the Afri-
can Horse Sickness virus antigens, and the like. In addition, 
the multivalent vaccine may include, but is not limited to, 
bacteria or bacterial toxoids acting as an additional antigen 
such as tetanus toxoid, live or inactivated Streptococcus 
equi, live recombinant vectors expressing S. equi antigens, 
live Rhodococcus equi, live recombinant vectors expressing a live vaccine, an adjuvant is not necessarily required in all 
formulations for achieving effective immunity. If it is desir-
able to include an adjuvant, for example, in a formulation 
designed for the intramuscular route of administration, the 
65 R. equi antigens, leptospira antigens or live recombinant 
vectors expressing leptospira antigens, Clostridum difficile 
toxoid, live recombinant vectors expressing C. difficile anti-
US 9,642,908 B2 
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gens, etc. and protozoan antigens such as Sarcocystis neu-
rona or Neospora hughesi and the like. 
The new modified live viral vaccines ofthis invention are 
not restricted to any particular method of preparation but can 
be made by standard methods known in the art. To prepare 5 
live, attenuated vaccines from the pathogenic virus, for 
instance, the tissue culture adapted, live, pathogenic EHV-1 
is attenuated (rendered nonpathogenic or harmless) by meth-
ods known in the art, typically through serial passages 
through cell cultures. One could employ the techniques 10 
described by C. T. Rosas et al., "Equine herpesvirus type 1 
modified live virus vaccines: quo vaditis?" Review, Expert 
Rev. Vaccines 5(1):119-131 (2006) that show how to gen-
erate RacH and Kentucky A (KyA) EHV-1 strains by con-
tinuous in vitro passages. Attenuation of the pathogenic 15 
EHV-1 virus may also be done by gene deletions, gene 
insertions or viral-producing gene mutations involving 
many different genes such as, for example, the IR6 (inverted 
repeat region 6), the gene regions encoding proteins gl, gE, 
gM and gG, the thymidine kinase (TK) or immediate early 20 
(IE) genes and 75 genes located in the Unique Short region 
(US) as well as combinations thereof (C. T. Rosas et al., id.; 
U.S. Pat. No. 6,225,111; U.S. Pat. No. 6,193,983; U.S. Pat. 
No. 5,741,696; U.S. Pat. No. 5,731,188; U.S. Pat. No. 
5,674,499 and U.S. Pat. No. 5,292,653; U.S. Published 25 
Patent Application No. 2007/0166330; U.S. Published Pat-
ent Application No. 2004/0109873; U.S. Published Patent 
Application No. 2004/063095; U.S. Published Patent Appli-
cation No. 2003/0059934 and U.S. Published Patent Appli-
cation No. 2003/198650; WO 2002/009750, among others). 30 
As the terms are used in conjunction with the present 
invention, a "low" pre-exposure level of herpesvirus-spe-
cific CTL precursors (i.e., the level of lymphocytes in the 
blood possessing lethal activity against EHV-1) before the 
horse is exposed to the herpesvirus means a measurement of 35 
approximately 40 or lower, preferably, lower than 20 and 
more preferably, less than 10 per 106 PBMC ( equine periph-
eral blood mononuclear cells). The "high" levels of post-
infection, leukocyte-associated viremia (i.e., the magnitude 
of EHV-1 virus present in the blood of horses) refer to a 40 
comparative measurement of approximately 10-fold or more 
over an arbitrarily selected standard level (that is, the level 
of EHV-1 present in the blood of horses four days after 
infection with a non-neuropathogenic strain of the virus), 
preferably, higher than 100-fold over the standard and more 45 
preferably, greater than 1000-fold higher than the standard 
level of the non-neuropathogenic virus. An effective infect-
ing amount of a neuropathogenic strain of EHV-1 refers to 
the amount of virus that produces a neurological infection in 
the horse such as, for example, 107 PFU (plaque forming 50 
units) of the neuropathogenic T953 strain ofEHV-1 (ORF30 
G2254), though it is contemplated that the effective infecting 
amount is readily titrated by routine methods taking the 
virulence of the virus, the weight of the horse, the age of the 
horse, etc. into consideration. When a given value is 55 
expressed as "approximate," "about" or similar terms, it 
should be understood that the variation refers to acceptable 
standard deviations of data in the field, for instance, ±5% of 
the value, within six months of the specified ages of approxi-
mately 20 (i.e., can be six months younger than age 20) or 60 
one year of age ( can be six months over), or within a day less 
than the one week old foal described herein. 
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Manassas, Va. 20110-2209, U.S.A. Specifically, the EHV-1 
T953 sample has been deposited in the ATCC on Jun. 19, 
2008 and has been assigned ATCC® Patent Deposit Desig-
nation PTA-9273. 
The following examples demonstrate certain aspects of 
the present invention. However, it is to be understood that 
these examples are for illustration only and do not purport to 
be wholly definitive as to conditions and scope of this 
invention. It should be appreciated that when typical reac-
tion or experimental conditions (e.g., temperature, reaction 
times, etc.) have been given, the conditions both above and 
below the specified ranges can also be used, though gener-
ally less conveniently. The examples are conducted at room 
temperature (about 23° C. to about 28° C.) and at atmo-
spheric pressure. All parts and percents referred to herein are 
on a weight basis and all temperatures are expressed in 
degrees centigrade unless otherwise specified. 
A further understanding of the present invention may be 
obtained from the examples that follow below. These work-
ing examples are intended to illustrate the invention without 
limiting its scope. 
EXAMPLES 1-4 
Materials and Methods 
Experimental Animals: 
The experimental sample of animals used in these studies 
consisted of 36 adult horse mares ranging in age from 4 to 
28 years. Twenty-five of the experimental horses were 
Thoroughbred broodmares donated to the M. H. Gluck 
Equine Research Center (Department of Veterinary Science, 
University of Kentucky, Lexington, Ky.) by local breeding 
farms, while the remaining 11 mixed-breed mares were 
provided from the experimental horse herd maintained by 
the University of Kentucky's equine research farm. None of 
the horses had been vaccinated for EHV-1 during the year 
preceding their use in these studies. For experimental infec-
tion with EHV-1, the horses were kept as 3 randomly 
assigned groups of 12 animals/group in half-acre, grassy lots 
at the University's equine isolation facilities. Daily health 
inspections, feeding and watering, preventive health activi-
ties ( e.g., fly and parasite control, hoof care, vaccinations, 
etc.), and handling and restraint for experimental procedures 
were provided by farm personnel. Antipyretic, anti-inflam-
matory and analgesic medications were administered, as 
prescribed by the IACUC-approved experimental, protocol, 
by the principal investigator. Veterinary services (including 
bladder catheterization, euthanasia, antibiotic therapy, etc.) 
were performed, as needed, by experienced equine practi-
tioners from a local veterinary practice. Following comple-
tion of the experimental procedures, the 30 equine survivors 
of infection by EHV-1 were returned to the resident horse 
population of the University's equine research farm. 
Virus Strains: 
A live, low-passaged, abortigenic strain of EHV-1 (Ky 
T262) was used for intra-nasal inoculation of 12 of the 
experimental horses. EHV-1 strain Ky T262 was isolated 
from an aborted equine fetus during a large-scale outbreak 
of herpesviral abortion ("abortion storm") on a commercial 
Kentucky Thoroughbred breeding farm in 1975. Its ORF30-
2254 genotype was determined by DNA sequencing using 
routine methods to be A2254 (J. Nugent et al., "Analysis of 
equine herpesvirus type 1 strain variation reveals a point 
For purposes of this invention, the neuropathogenic T953 
strain of EHV-1 has been deposited under the conditions 
mandated by 37 C.F.R. §1.808 and maintained pursuant to 
the Budapest Treaty in the ATCC® (American Type Culture 
Collection) Patent Depository, University Boulevard, 
65 mutation of the DNA polymerase strongly associated with 
neuropathogenic versus non-neuropathogenic disease out-
breaks," J Viral 80:4047-4060 (2006)). 
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A live, low-passaged, neuropathogenic strain of EHV-1 
(Ky T953) was used for intra-nasal inoculation of 24 of the 
experimental horses. EHV-1 strain T953 was isolated from 
the blood leukocytes of an adult horse that developed 
quadriplegia during a multiple-case epizootic of EHV-1 
myeloencephalopathy at a university equestrian center in 
Ohio in 2003 (R. W. Henninger et al., "Outbreak of Neu-
rologic Disease Caused by Equine Herpesvirus-1 at a Uni-
versity Equestrian Center," J Vet Intern Med 21:157-165 
(2007)). Its ORF30-2254 genotype was determined by DNA 
sequencing using routine methods to be G2254 (J. Nugent et 
al., "Analysis of equine herpesvirus type 1 strain variation 
reveals a point mutation of the DNA polymerase strongly 
associated with neuropathogenic versus non-neuropatho-
genic disease outbreaks," J Viral 80:4047-4060 (2006)). 
Both strains of EHV-1 were originally isolated in mono-
layers of an equine dermal fibroblast cell line and propa-
gated at low multiplicity of infection (moi=0.1) using the 
same cell line for production of the virus stocks used for 
horse inoculation. 
Inoculation of Horses with EHV-1: 
Preinfection blood and nasopharyngeal samples were 
collected, and baseline rectal temperatures were recorded. 
To initiate viral infection, each horse was inoculated intra-
nasally with 107 plaque-forming units (PFU) of EHV-1 by 
use of a fenestrated, 30.5 cm (12 inch) rubber catheter. The 
course of infection was followed by daily monitoring of 
clinical signs and rectal temperatures. Nasopharyngeal 
secretions were collected daily for 7 days with 16-inch, 
flexible, rayon-tipped swabs (for example, PROCTO 
SWAB® commercially available from Henry Schein, Inc., 
Melville, N.Y.) and processed for virus isolation by inocu-
lation of monolayers of equine dermal cells. Both coagu-
lated and heparinized venous blood samples were collected 
at 2, 4, 6, 8, 10, 12, 14 and 21 days post inoculation and 
processed for serum and peripheral blood mononuclear cells 
(PBMC), respectively. 
The severity of clinical neurologic signs in the EHV-1 
inoculated horses was graded using a simplification of the 
scale described by Mayhew (I. Mayhew, "Evaluation of the 
large animal neurological patient," Large Animal Neurol-
ogy: A Handbook for Veterinary Clinicians 1989, Philadel-
phia, ed., Lea & Febiger, pp 3-69). The observed neurologic 
deficits were categorized and recorded as either grade 1 
(decreased tail muscle tone or toe-dragging), grade 2 (any 
other walking gait abnormality or bladder atony ), or grade 3 
(recumbency). 
Preparation of DNA from Equine Peripheral Blood Mono-
nuclear Cells (PBMC): 
PBMC were purified by Ficoll-Hypaque centrifugation of 
heparinized venous blood samples collected from horses 
inoculated with EHV-1 (using, for example, Ficoll-Paque 
PLUS® commercially available from GE Healthcare, Pis-
cataway, N.J.) as previously reported (G. P. Allen and C. C. 
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Breathnach, "Quantification by real-time PCR of the mag-
nitude and duration of leukocyte-associated viraemia in 
horses infected with neuropathogenic versus non-neuro-
pathogenic strains of equine herpesvirus-1," Equine Vet J 
5 38:252-257 (2006)). For each test sample, RNA-free total 
DNA was isolated from 5xl07 PBMCs using a commercial 
kit designed for purification of genomic DNA from blood 
leukocytes (for example, Wizard Genomic DNA Purification 
Kit® commercially available from Promega, Madison, 
10 Wis.). Purified DNA was dissolved in 200 µL of sterile water 
and quantified via measurement of absorbance at 260 nm. 
Real-Time PCR Quantification of EHV-1 DNA: 
A real-time PCR assay was used for quantitative detection 
15 of EHV-1 DNA present in peripheral blood mononuclear 
cells of horses following experimental inoculation of EHV-1 
in accordance with conventional techniques previously 
described (G. P. Allen and C. C. Breathnach, 2006, id). The 
assay was performed using TaqMan® detection chemistry 
20 (commercially available from Applied Biosystems, Foster 
City, Calif.) and the 7500 Real-Time PCR system (using, for 
example, 7500 SDS Software®, ver. 1.3.1, commercially 
available from Applied Biosystems, Foster City, Calif.). The 
real-time amplification primers and TaqMan® fluorescent 
25 detection probes used are listed in the below Table 1. For 
each DNA sample, triplicate real-time PCR reactions were 
run, each containing 1 µg of PBMC DNA in 25 µL of 
complete PCR reaction mixture with 900 nM primers 
designed to amplify a 60 bp fragment of the EHV-1 glyco-
30 protein B (gB) gene, and 250 nM fluorescent (5'-FAM) 
TaqMan® probe for real-time detection of the amplified gB 
sequence. As an endogenous control for normalization of 
sample-to-sample variations in the amount of target DNA 
35 added to the reaction wells, 3 different replicates of each 
sample were run with the gB primer/probe set replaced with 
a primer pair and fluorescent probe for detection of the 
equine ~-actin gene sequence (Table 1 ). Amplification 
parameters consisted of an initial denaturation step of 95° C. 
40 for 10 minutes followed by 45 cycles of 95° C. for 15 
seconds and 60° C. for 1 minute. Quantitative comparison 
and statistical analysis of the results were performed by 
7500 SDS Software® (ver. 1.3.1, commercially available 
from Applied Biosystems, Foster City, Calif.), using the 
45 Delta-Delta-Cr relative quantification method for expressing 
observed quantitative differences in levels of EHV-1 DNA 
(K. J. Livak and T. D. Schmittgen, "Analysis ofrelative gene 
expression data using real-time quantitative PCR and the 
Delta-Delta Cr method," Methods 25:402-408 (2001)). The 
50 quality control parameters (specificity, sensitivity, dynamic 
range, efficiency of amplification) and characteristics of the 
calibrator DNA for the real-time PCR assay have been 
described previously (G. P. Allen and C. C. Breathnach, 
2006, supra). 
TABLE 1 
Real-time PCR oliqo primers and fluorescent detection probes used in the study 
Primer/probe 
EHVlGB-JNlF 
EHVlGB-JNlR 
EHVlGB-JNlMl 
Sequence ( 5' to 3') Target DNA 
CTG CCC CTG GAG GTG TAC (SEQ ID NO, 1) EHV-1 gB 
TTG CGG CGC TGT ATT TCG (SEQ ID NO, 2) EHV-1 gB 
FAM-CAC CGG CCT GCT AGA CT-NFQ EHV-1 gB 
(SEQ ID NO, 3 with minor groove binder adduct) 
EQBACTINIS-JN3F CCC CGA GGC CCT CTT C (SEQ ID NO, 4) Equine 13-actin 
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TABLE 1-continued 
Real-time PCR oligo primers and fluorescent detection probes used in the study 
Primer/probe Sequence (5' to 3') Target DNA 
EQBACTINIS-JN3R GA GTT GAA GGT AGT TTC GTG GAT (SEQ ID NO, 5) Equine ~-actin 
EQBACTINIS-JN3Ml FAM-CCC TCC UC CTG GGC ATG-NFQ Equine ~-actin 
(SEQ ID NO, 6 with minor groove binder adduct) 
FAM = 6 carboxyfluorescein reporter fluoroprobe; 
NFQ = non-fluorescent quencher moiety 
Determination of CTLp Frequency: nificance by analysis of 2x2 contingency tables by Fisher's 
15 exact test of independence. Significance of differences 
between experimental horse groups in numerical variables 
(e.g., viremic load or CTLp frequency) was tested by 
one-way analysis of variance. The significance of an 
observed linear relationship between two measured numeri-
Estimation of the frequency of EHV-1 specific CTL 
precursors (CTLp) present in the peripheral blood circula-
tion of horses was done by a limiting dilution microculture 
system developed by O'Neill et al. (T. O'Neill et al., 
"Determination of equid herpesvirus I-specific, CDS+, cyto-
toxic T lymphocyte precursor frequencies in ponies," Vet 
Immunol & Immunopathol 70:43-54 (1999)). Seven, two-
fold dilutions of PBMC responder cells were cultured in 
vitro with autologous, stimulator PBMCs that expressed 
EHV-1 antigens. Stimulator PBMCs were generated by 
infection with 10 PFU ofEHV-1 (Army-183 strain) per cell 
for 90 minutes followed by a 30-minute treatment at 37° C. 
with 25 µg/mL mitomycin-C to block proliferation of the 
stimulator cells during culture. Twenty-four, 200-µL repli-
cates of each responder cell dilution were co-cultivated in 
96-well round-bottomed microplates with 50,000 stimulator 30 
PBMC which functioned as antigen-presenting cells and 
feeder cells for support of single-cell clonal growth of 
CTLp. After 10 days of incubation at 37° C. in the presence 
20 cal variables ( e.g., viremic load and CTLp frequency or 
viremic load and SNA titer) was examined by linear least 
squares regression analysis. Statistically significant relation-
ships between one categorical variable (e.g., occurrence of 
disease) and one numerical variable ( e.g., pre-exposure 
25 CTLp frequency or pre-exposure SNA titer) were estab-
lished by logistic regression analysis. 
of 10 Units ofrecombinant human interleukin-2 (rH-IL-2), 
the induction cultures were assayed for cytolytic activity 35 
against chromium-51 (Cr-51) labeled, EHV-1 (Amy-183 
strain) infected lymphoblast targets (pokeweed mitogen 
stimulated PBMC), using standard techniques as described 
Example 1 
Relationship Among CTLp Frequency, EHV-1 
Viremia and Development of Neurologic Disease 
To summarize the study design, 36 horse mares were used 
for all of the studies described herein. The 24 elderly horses 
(>20 years) were randomly assigned to either of two experi-
mental groups of 12 horses each (groups A and B). The 
remaining 12, younger horses ( <15 years) comprised experi-
mental group C. All 24 animals in groups A and C were 
inoculated with 107 PFU (plaque forming units) of a neu-
ropathogenic strain ofEHV-1 (T953). The 12 group B horses 
were inoculated with 107 PFU of a non-neuropathogenic 
strain ofEHV-1 (T262). Statistical comparisons ofresponse 
variables ( e.g., development of neurologic signs, magnitude 
of viremia, etc.) were made between experimental horse 
groups that differed in one or more predictor variables (e.g., 
challenge strain of EHV-1, age-category, breed, pre-expo-
sure levels of CTLp or SNA titers, etc.). 
Nine of the 24 horses inoculated with the neuropathogenic 
strain of EHV-1 (Ky T953) developed clinical signs of 
central nervous system disease. Grade 2 neurologic deficits 
were present in three of the horses, while the remaining six 
animals displayed grade 3 neurologic signs. A scatter plot 
graphical summarization of the relationship between the two 
numerical variables "post-infection viremic load" (y axis) 
by O'Neill et al. (1999, id.). The amount of Cr-51 released 
into each culture well was determined after a 4-hour incu- 40 
bation with 10,000 target cells by counting 200-µL of cell 
free supernatant from each well in a gamma counter. Spon-
taneous Cr-51 release by target cells was determined in wells 
without responder cells, and maximal Cr-51 release was 
measured in wells containing 0.05% NP-40 detergent. A 45 
culture well was scored as lysis-positive if the supernatant 
counts per minute (cpm) ofCr-51 exceeded by >2-fold the 
mean spontaneous Cr-51 release. Frequencies of CTLp in 
the blood of each horse were calculated by using the 
statistical evaluation software program of Strijbosch et al. 50 
(L. W. Strijbosch et al., "Limiting dilution assays: Experi-
mental design and statistical analysis," J Immunol Meth 
97:133-40 (1987)). The frequencies ofCTL precursors spe-
cific for EHV-1 are expressed as CTLp per million responder 
PBMC. 55 and "pre-exposure CTLp frequency" (x axis) for the 24 
EHV-1 inoculated horses is shown in FIG. 1 ( open and filled 
circles). The nine horses that developed clinical signs of 
neurological disease ( categorical variable) following EHV-1 
challenge infection are indicated on the plot by the open 
Determination of Serum Neutralizing Antibody Titer: 
Measurement of EHV-1 serum neutralizing antibody 
(SNA) titers was performed by a standard microneutraliza-
tion assay described previously (C. C. Breathnach et al., 
"The mucosa! humoral immune response of the horse to 
infective challenge and vaccination with equine herpesvi-
rus-1 antigens," Equine Vet J 33:651-657 (2001)). 
Statistical Analysis: 
Differences observed between experimental groups of 
horses in two categorical variables (e.g., age category and 
occurrence of neurologic disease or virus strain and occur-
rence of neurologic disease) were tested for statistical sig-
60 circles. The differences between the two age groups of mares 
in their mean magnitude of EHV-1 viremia are significant at 
P=2:0.05 for after inoculation days 4 through 10. Because the 
appearance of the scatter plot indicated a fairly strong linear 
relationship between the individual values of the two param-
65 eters "pre-infection CTLp frequency" and "post-infection 
viremic load," a linear regression line (solid line) was fitted 
to the data points using the least squares computational 
US 9,642,908 B2 
21 
method (for example, SigmaStat® 3.1 statistical analysis 
software commercially available from SYSTAT Software, 
Inc., Point Richmond, Calif.). 
The linear relationship between the two numerical values 
may be summarized by the slope-intercept equation, y=a+ 5 
bx, where "a" is they-intercept and the slope is represented 
22 
greater risk for post-exposure development of EHV-1 neu-
rologic signs in elderly (>20 years) horses than in horses less 
than 15 years of age. 
The data were also analyzed for a breed effect on the 
development of post-infection EHV-1 neurological disease 
in the 24 horses. The proportion of horses that developed 
clinical neurological signs in the two breed categories of 
horses (Thoroughbred and mixed-breed mares) was not 
significantly different than expected from random occur-
rence (P=0.41). 
To explore the biological basis underlying the greater 
susceptibility of aged (elderly) horses to EHV-1 myeloen-
cephalopathy, the magnitude of post-inoculation cell-asso-
ciated viremia that developed in the two age-categories of 
as the number "b" value multiplied by the "x" value to 
obtain where the line crosses the y-axis. In terms of the 
present invention, "peak viremic load" (y value )=2.97 (y-in-
tercept a value)+-0.027 (slope b value) X "pre-infection 10 
CTLp frequency" (x value). The correlation coefficient 
statistic r between the two numerical variables was -0.79. 
Simply stated, the regression line relationship can be reli-
ably used to predict the magnitude of viremia following 
EHV-1 infection of a horse and its subsequent likelihood for 
development of neurologic signs, given the pre-infection 
frequency of the horses's circulating, virus-specific CTLp. 
Using the statistic, r2 , as a measure of scatter of the observed 
data points from the regression line, 62% of the value of the 
post-exposure magnitude of EHV-1 viremia in an exposed 
horse can be accounted for by the value of the variable 
"pre-exposure frequency of EHV-1 specific CTLp." The 
computed statistical probability (P value) that no straight-
line relationship exists between the numerical values of 25 
"pre-exposure CTLp" and "post-exposure viremic load" was 
P=<0.001. 
15 mares was measured and compared (FIG. 2). Statistical 
significances of the observed differences in the mean vire-
mic loads between the two age categories of horses were 
calculated by one-way analysis of variance. The differences 
between the two age groups of mares in their mean magni-
20 tude of EHV-1 viremia were significant at P=s0.05 for 
post-inoculation days 4 through 10. The magnitude of 
EHV-1 viremia was greater in the elderly category of mares 
at all times post-infection, with levels ranging from 10- to 
200-fold higher than in the younger mares. 
Of particular clinical significance was the observation that 
all nine horses that developed neurologic signs ( open circles, 
FIG. 1) after inoculation with a neuropathogenic strain of 30 
EHV-1 possessed the combination of low CTLp frequency 
and high viremic load. Statistical significances of the 
observed differences in the mean viremic loads between the 
two age categories of horses were calculated by one way 35 
analysis of variance. 
Example 2 
Example 3 
Relationship Between EHV-1 Genotype and 
Post-Exposure Development of Equine Neurologic 
Disease 
To test the hypothesis that ORF30 G2254 strains ofEHV-1 
pose a greater risk than A2254 strains for causing EHV-1 
myeloencephalopathy, 12 elderly (>20 years) mares were 
inoculated intranasally with 107 PFU (plaque forming units) 
of the abortigenic T262 strain of EHV-1 (ORF30 A2254) and 
12 other elderly mares were inoculated with 107 PFU of the 
neuropathogenic T953 strain ofEHV-1 (ORF30 G2254). All 
24 of the mares possessed low pre-inoculation levels of 
Relationship Between Age of EHV-1 Exposed 
Horse and Development of Neurological Disease 
The association between "mare age-category" and post-
inoculation development of "clinical signs of EHV-1 neu-
rological disease" was examined. The null hypothesis was 
that, following inoculation of mares of different age catego-
ries with neuropathogenic EHV-1, the incidence of neuro-
logical disease would be the same in young ( <15 years) and 
elderly (>20 years) age categories of horses. 
40 EHV-1 specific CTLp ( <40 per 106 PBMC). While none of 
the aged horses exposed to the abortigenic strain (T262) of 
EHV-1 exhibited neurologic signs, 8 of the 12 elderly horses 
exposed to the neuropathogenic strain (T953) of the herpes-
virus developed clinical neurological disease (two grade 2 
45 and six grade 3 neurologic cases). 
The virological basis for the differing levels of neuro-
pathogenicity possessed by the two ENV-1 genotypes was 
explored by comparison of the magnitude of leukocyte-
associated viremia exhibited by the two experimental treat-
50 ment groups of horses (FIG. 3). The differences in the mean 
magnitude of EHV-1 viremia resulting from inoculation 
with the two genetic strains of EHV-1 are significant at 
P=s0.05 for post inoculation days 4 through 12. 
To test the hypothesis, 12 mares belonging to each of the 
two age groups (<15 years or >20 years) were inoculated 
intranasally with 107 PFU (plaque forming units) of a 
neuropathogenic strain of EHV-1 (T953) and observed twice 
daily for 3 weeks for neurologic signs. Only one mare from 
the <15 y age category exhibited post-inoculation neuro-
logic signs consisting of hindlimb incoordination and drib-
bling of urine (grade 2) that necessitated the placement of an 
indwelling urinary catheter. The mare made a full recovery 
after 2 weeks. In contrast, 8 of the 12 EHV-1 inoculated 
elderly mares developed clinical signs of neurologic disease. 60 
Two of the neurologically affected old mares were ataxic 
only or ataxic with urinary bladder atony (grade 2), while the 
remaining 6 developed lateral recumbency (grade 3) and 
were euthanized. 
At all sampling times following virus inoculation, the 
55 circulating viremic load was significantly greater in the 
group of 12 horses exposed to the ORF30 G2254 genotype 
(T953) of EHV-1. 
Using Fisher's exact test for analysis of the experimental 65 
data, the P-value statistic was 0.009, indicating that the null 
hypothesis can be rejected and that there is a significantly 
Example 4 
Relationship Between Pre-Exposure SNA Titer to 
EHV-1 and Post-Exposure Development of Equine 
Neurologic Disease 
For the 24 horses inoculated with the neuropathogenic 
strain of EHV-1 (T953), quantitative measurements of 
EHV-1 specific, serum neutralizing antibody (SNA) present 
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?t t~e time of virus challenge were done by microneutral-
1zat10n assays (FIG. 4). The correlation coefficient r 
between the two plotted variables is 0.31. The statistical 
probability (P value) that no linear relationship exists 
between pre-exposure SNA titer and magnitude of post- 5 
exposure EHV-1 viremia is 0.144. No significant association 
was detected between pre-exposure SNA titers and the 
magnitude of post-infection EHV-1 viremia. Likewise, no 
significant correlation between resistance of horses to 
EHV-1 neurological disease and pre-exposure levels of 10 
serum neutralizing antibody against the virus could be 
demonstrated. 
Example 5 
24 
In the foregoing, there has been provided a detailed 
description of particular embodiments of the present inven-
tion for purpose of illustration and not limitation. It is to be 
understood that all other modifications, ramifications and 
equivalents obvious to those having skill in the art based on 
this disclosure are intended to be included within the scope 
of the invention as claimed. 
What is claimed is: 
1. An equine vaccine comprising a nontoxic, physiologi-
cally acceptable carrier and an immunogenic amount of a 
live, attenuated neuropathogenic strain of EHV-1 compris-
ing the EHV-1 strain T953, wherein the neuropathogenic 
strain is attenuated by serial passages and the vaccine 
protects a horse from a neurologic form of EHV-1 disease. 
Determination of Immune Protection Against 
EHV-1 Neurologic Disease Using Experimental 
Horse Model of Present Invention 
15 2. The equine vaccine according to claim 1, further 
comprising an antigen selected from the group consisting of: 
EHV-4, EHV-5, Equine Influenza Virus, Eastern Encepha-
lomyelitis Virus, Western Encephalomyelitis Virus, Venezu-
elan Encephalomyelitis Virus, West Nile Virus, African Twenty-four elderly horses comprised the experimental 
animal study sample. Twelve horses randomly selected from 
the group were vaccinated by intranasal inoculation with a 
live, non-neuropathogenic abortion isolate of Ky T262 
EHV-1. The remaining 12 horses were housed in separate 
facilities and sham-vaccinated by intranasal inoculation of 
20 Horse Sickness Virus, tetanus toxoid, Streptococcus equi, 
Rhodococcus equi, leptospira, Clostridum difficile, Sarco-
cystis neurona, Neospora hughesi, a recombinant protein or 
a recombinant vector expressing a protein derived therefrom 
culture medium from uninfected tissue culture cells. 
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and a combination thereof. 
3. The equine vaccine according to claim 1, further 
comprising an adjuvant. 
4. The equine vaccine according to claim 3, wherein the 
adjuvant comprises squalane and a polyoxypropylene-poly-
oxyethylene block copolymer. 
Ninety days after vaccination or sham-vaccination all 24 
experimental horses were challenged by intranasal i~ocula-
tion with the neuropathogenic isolate ofEHV-1 (T953). The 
challenged horses were evaluated daily for fever, nasal 
discharge and neurologic dysfunction. Serum samples and 
PBMC were collected for 21 days post-challenge for deter-
mination of antibody titers and quantitative levels of EHV-1 
viremia. As a measure of CTL activity, PBMC samples 
collected from each experimental horse were also analyzed 
for the presence of EHV-1 specific, IFN-gamma expressing 
cytotoxic CDS+ T-lymphocytes. 
30 5. A method of protecting a horse against neurologic 
disease or viral infection caused by a neuropathogenic strain 
of EHV-1 comprising administering to the horse in need of 
protection an immunologically effective amount of the 
equine vaccine according to claim 1. 
35 6. The method according to claim 5, which comprises 
The results of the vaccination-challenge study were ana-
lyzed by Fisher's exact test which identified a statistically 
significant reduction in the frequency of post-challenge 40 
EHV-1 neurologic disorders in the vaccinated group of 
horses and validated the utility of the vaccination-challenge 
model. Surprisingly, the live, non-neuropathogenic isolate of 
EHV-1 (ORF30 A2254 genotype) was able to afford protec-
tion against EHV-1 neurologic disease. In sum, this vacci-
. ~ 
nat10n-challenge study design finds use in the identification 
of live vaccine candidates that protect against neurological 
disease. 
administering the vaccine orally, intranasally, intramuscu-
larly, intrarectally, transdermally or intradermally to the 
horse. 
7. The method according to claim 5, further comprising 
administering an adjuvant immediately before, during or 
after the equine vaccine is administered or alternatively 
administering the equine vaccine further cont~ining an adju~ 
vant. 
8. The method according to claim 7, wherein the adjuvant 
comprises squalane and a polyoxypropylene-polyoxyethyl-
ene block copolymer. 
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